Invitae Common Hereditary Cancers + RNA Panel
Use
The Invitae Common Hereditary Cancers + RNA Panel analyzes genes associated with adult-onset, nonsyndromic predisposition to several hereditary cancer types, including breast, ovarian, uterine, prostate, and gastrointestinal cancers. This test facilitates the diagnosis and management of these conditions by offering broad panel testing, which accounts for the genetic heterogeneity and clinical overlap seen in these cancers. It enables early detection of symptoms, informs family planning, and can support clinical trial enrollment. The RNA testing component aids in identifying and interpreting variants in selected genes, enhancing the test's diagnostic utility.
Special Instructions
This test is designed for detecting heritable germline mutations and is not suitable for analyzing somatic mutations in tumor tissue. RNA testing complements the DNA analysis by improving variant interpretation. It is crucial for clinicians to provide appropriate specimens to ensure accurate testing, and they may customize the panel by removing genes. For further details on disorders tested or to customize the test, clinicians should visit the provided links and order the necessary collection kits.
Limitations
The test has >99% analytical sensitivity for single nucleotide variants, small insertions, and deletions, but sensitivity decreases for larger variants. Structural rearrangements or complex variants may not be detected, and some sequence properties can limit detection of single-exon events. The RNA component primarily supports DNA variant interpretation and doesn't inform copy number variations. Full variant resolution, including details about mosaicism or phasing, is not guaranteed unless specified.
New York Approved
Methodology
NGS (Targeted)
Biomarkers
Result Turnaround Time
10-21 days
Related Documents
For more information, please review the documents below
Specimen
Whole Blood
Volume
3 mL
Minimum Volume
Not provided
Container
purple-top EDTA tube